# US 2020/0347072 A1 · Tricyclic Compounds Useful to Treat Orthomyxovirus Infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347072 A1
- Document ID: US20200347072A1
- Status: Published application
- Kind: A1
- Application number: 16/933,000
- Filed: 2020-07-20
- Published: 2020-11-05
- Earliest claimed: 2016-03-08
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Rama JAIN; Dennis Christofer KOESTER; James R. MANNING; James Clifford SUTTON; Benjamin Robert TAFT; Lifeng WAN; Qian ZHAO
- Web page: https://patentgrep.com/patent/US20200347072A1

## CPC

- C07D 487/14: Ortho-condensed systems
- A61P 31/16: for influenza or rhinoviruses
- C07D 471/14: Ortho-condensed systems
- C07D 491/22: in which the condensed system contains four or more hetero rings
- C07D 498/14: Ortho-condensed systems
- C07D 513/14: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: (I) and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions to treat viral infections.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
G is H or a group selected from —C(O)R, —C(O)—OR, —C(RG)2—O—C(O)R, —C(RG)2—O—C(O)—OR, —C(O)—NR2, and —C(RG)2—O—C(O)NR2, where each R is independently H or a group selected from C1-C4 alkyl, phenyl, pyridyl, C3-C7 cycloalkyl, and a 3-6 membered heterocyclic ring containing one or two heteroatoms selected from N, O and S as ring members; and each R that is not H is optionally substituted with one or two groups selected from halo, CN, —OH, amino, C1-4 alkyl, phenyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy;
and each RG is independently selected from H and C1-4 alkyl;
X1 is CRX1 or N, where RX1 is H, halo, C1-6 alkyl, C1-4 haloalkyl, CN, COOH, or a 5-6 membered heteroaryl ring containing 1-4 heteroatoms selected from N, O and S as ring members and optionally substituted by 1-2 groups selected from halo, hydroxy, amino, C1-3 alkyl, C1-3 haloalkyl, and C1-3 alkoxy;
X2 is CRX2 or N, where RX2 is H, halo, C1-6 alkyl or C1-4 haloalkyl;
X3 is CRX3 or N, where RX3 is H, C1-4 alkyl or C1-4 haloalkyl;
provided that X2 is CRX2 if either or both of X1 and X3 represent N;
R1 is H, halo, hydroxy, C1-4 alkyl, C1-4 haloalkyl, or C1-4 alkoxy;
R2 and R3 are independently H, C1-4 alkyl or C3-5 cycloalkyl, wherein each C1-4 alkyl and C3-5 cycloalkyl is optionally substituted with one or two groups selected from halo, CN, —OH, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy;
or R2 and R3 taken together with the carbon atom to which both are attached can form a 3-5 membered cycloalkyl ring or a 3-5 membered cyclic ether ring having one oxygen as a ring member;
Ring A is a five-membered heteroaryl ring containing at least one carbon ring atom and up to four heteroatoms selected from N, O and S as ring members, wherein
Z1 is N, O or S;
Z2 and Z3 are independently CRz, N, NRz, O or S; and
Z4 and Z5 each independently represent C or N,
provided Z4 and Z5 are not both simultaneously N,
where each Rz is independently selected from H, halo, C1-4 alkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl containing one or two heteroatoms selected from N, O and S as ring members, C1-4 alkoxy, CN, CON(R4)2 and C1-4 haloalkyl, wherein the C1-4 alkyl is optionally substituted with one or two groups selected from —OR4, —N(R4)2, COOR4, CON(R4)2, and a 5-6 membered heterocyclic ring containing one or two heteroatoms selected from N, O and S as ring members;
R4 at each occurrence is independently selected from H, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, phenyl, a 5-6 membered heterocyclic ring containing one or two heteroatoms selected from N, O and S as ring members, wherein the C1-4 alkyl, C3-6 cycloalkyl, phenyl, and 5-6 membered heterocyclic ring containing one or two heteroatoms selected from N, O and S as ring members are each optionally substituted with one or two groups independently selected from halo, —OH, C1-2 alkyl, and —O(C1-2 alkyl);
and two R4 groups directly attached to the same nitrogen atom can optionally be taken together to form a 4-6 membered heterocycle optionally containing an additional heteroatom selected from N, O and S as a ring member and optionally substituted with one or two groups selected from halo, —OH, C1-2 alkyl, and —O(C1-2 alkyl);
Ar1 and Ar2 each represent phenyl or a 5-6 membered heteroaryl ring containing 1-3 heteroatoms selected from N, O and S as ring members, and are each independently substituted with up to three groups selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C2-4 alkyne, —S(C1-3 alkyl), —SO2(C1-3 alkyl), and CN;
and Ar1 and Ar2 are optionally linked together by a bridge of the formula —C(RL)2-L- to form a tricyclic ring system wherein each Ar1 and Ar2 is optionally substituted by up to two groups independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C2-4 alkyne, —S(C1-3 alkyl), —SO2(C1-3 alkyl), and CN,
where L is selected from S, S═O, SO2, O, C(RL)2 and CF2,
and each RL is independently H or C1-2 alkyl.

### Claim 2 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X1 is CH.

### Claim 3 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X2 is CH or N.

### Claim 4 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X3 is CH.

### Claim 5 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 and R3 are both H.

### Claim 6 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is H.

### Claim 7 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Ring A is selected from imidazole, pyrazole, triazole, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, and tetrazole.

### Claim 8 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Z5 is C.

### Claim 9 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Z4 is N.

### Claim 10 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Z3 is CRz or N.

### Claim 11 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein ring A is selected from imidazole, pyrazole, triazole and tetrazole.

### Claim 12 (depends on 1)

The compound of claim 1, which is of the formula:
wherein Y represents a group selected from
wherein each Ry is independently selected from H, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C2-4 alkyne, and CN,
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1, wherein G is H.

### Claim 14 (depends on 1)

The compound of claim 1, wherein G is selected from —C(O)R, —C(O)—OR, —CH2—O—C(O)R and —CH2—O—C(O)—OR; wherein R is C1-C4 alkyl, optionally substituted with one or two groups selected from halo, CN, —OH, amino, phenyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy.

### Claim 15 (depends on 1)

The compound of claim 1, which is selected from the compounds in Table 1 and the pharmaceutically acceptable salts thereof.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

### Claim 17 (depends on 1)

A combination comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.

### Claim 18 (depends on 1)

A method of treating influenza, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

A compound according to claim 1 or a pharmaceutically acceptable salt thereof, for use as a medicament.

### Claim 20 (depends on 1)

A compound according to claim 1 or a pharmaceutically acceptable salt thereof, for use in the treatment of influenza.

### Claim 21

(canceled)
